Similarities and Differences in Patient Characteristics Between Heart Failure Registries Versus Clinical Trials
- 268 Downloads
Acute and chronic heart failure results in significant morbidity and mortality to patients and is a major concern for the healthcare systems. Various randomized controlled trials have demonstrated an improvement in morbidity and mortality for patients with heart failure. However, the findings of these trials are often applicable to a limited population. Several large-scale registries are now shedding insight as to the treatment, outcomes, and follow-up of patients in a real-life clinical setting. The objective of this review is to examine some of the heart failure therapies, such as cardiac resynchronization therapy, implantable cardioverter defibrillators and medications, in the context of randomized trials versus clinical registries. This review will also identify how registries are improving patient outcomes and how they are uncovering differences and gaps in treatment in non-randomized trial settings.
KeywordsClinical trials Epidemiology Registry Heart failure Pharmacologic therapy Implantable devices
Compliance with Ethics Guidelines
Conflict of Interest
Abhinav Sharma declares that he has no conflict of interest.
Justin A. Ezekowitz is supported by grants from Johnson & Johnson (ASCEND Clinical Trial Steering Committee) and Amgen (ATOMIC Clinical Trial Steering Committee).
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, et al. The 2012 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: focus on acute and chronic heart failure. CJCA. 2013;29(2):168–81.Google Scholar
- 3.McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847.PubMedCrossRefGoogle Scholar
- 4.Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, et al. Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):1977–2016.PubMedCrossRefGoogle Scholar
- 9.Gastelurrutia P, Lupón J, de Antonio M, Urrutia A, Díez C, Coll R, et al. Statins in heart failure: the paradox between large randomized clinical trials and real life. JMCP. 2012;87(6):555–60.Google Scholar
- 13.• Heidenreich PA, Hernandez AF, Yancy CW, Liang L, Peterson ED, Fonarow GC. Get with the guidelines program participation, process of care, and outcome for Medicare Patients Hospitalized With Heart Failure. Circ Cardiovasc Qual Outcomes. 2012;5(1):37–43. This reference highlights the feasibility of creating a large-scale registry that promotes adherence to clinical guidelines.PubMedCrossRefGoogle Scholar
- 14.Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585–96.PubMedCrossRefGoogle Scholar
- 22.Al-Khatib SM, Mi X, Wilkoff BL, Qualls LG, Frazier-Mills C, Setoguchi S, et al. Follow-up of Patients With New Cardiovascular Implantable Electronic Devices: are experts' recommendations implemented in routine clinical practice? Circ Arrhythm Electrophysiol. 2013;6(1):108–16.PubMedCrossRefGoogle Scholar
- 25.Medical Advisory Secretariat. Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis. Ontario Health Technology Assessment Series 2005;5(14).Google Scholar
- 28.• Boriani G, Diemberger I, Biffi M, Martignani C. Cost-effectiveness of cardiac resynchronisation therapy. Heart. 2012;98(24):1828–36. This reference provides a very comprehensive analysis of the cost effectiveness of CRT.Google Scholar
- 31.Shukla A, Curtis AB, Mehra MR, Albert NM, Gheorghiade M, Heywood JT, et al. Factors associated with improvement in utilization of cardiac resynchronization therapy in eligible heart failure patients: findings from IMPROVE HF. Pacing Clin Electrophysiol. 2013;36(4):433–43.PubMedCrossRefGoogle Scholar
- 35.Muus KJ, Knudson A, Klug MG, Gokun J, Sarrazin M, Kaboli P. Effect of postdischarge follow-up care on re-admissions among US veterans with congestive heart failure: a rural–urban comparison. Rural Rem Health. 2010;10(2):1447.Google Scholar
- 47.GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9645):1231–9.Google Scholar
- 49.•• Ezekowitz JA, Hu J, Delgado D, Hernandez AF, Kaul P, Leader R, et al. Acute heart failureclinical perspective perspectives from a randomized trial and a simultaneous registry. Circ Heart Fail. 2012;5(6):735–41. This excellent reference provides insight into the construction of a simultaneous RCT and registry.PubMedCrossRefGoogle Scholar